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ABSTRACT
Background. Inherited BRCA gene mutations convey a high risk for breast and
ovarian cancer, but current guidelines limit BRCA mutation testing to women with
early-onset cancer and relatives of mutation-positive cases. Beneﬁts and risks of
providingthisinformationdirectlytoconsumersareunknown.
Methods.Toassessandquantifyemotionalandbehavioralreactionsofconsumersto
their 23andMe Personal Genome Service
R  report of three BRCA mutations that are
commoninAshkenaziJews,weinvitedall136BRCA1andBRCA2mutation-positive
individuals in the 23andMe customer database who had chosen to view their BRCA
reports to participate in this IRB-approved study. We also invited 160 mutation-
negative customers who were matched for age, sex and ancestry. Semi-structured
phone interviews were completed for 32 mutation carriers, 16 women and 16 men,
and 31 non-carriers. Questions addressed personal and family history of cancer,
decisionandtimingofviewingtheBRCAreport,recollectionoftheresult,emotional
responses,perceptionofpersonalcancerrisk,informationsharing,andactionstaken
orplanned.
Results. Eleven women and 14 men had received the unexpected result that they are
carriers of a BRCA1 185delAG or 5382insC, or BRCA2 6174delT mutation. None of
themreportedextremeanxietyandfourexperiencedmoderateanxietythatwastran-
sitory.Remarkably,ﬁvewomenandsixmendescribedtheirresponseasneutral.Most
carrier women sought medical advice and four underwent risk-reducing procedures
after conﬁrmatory mutation testing. Male carriers realized that their test results im-
pliedgeneticriskforfemalerelatives,andseveralofthemfeltconsiderablyburdened
by this fact. Sharing mutation information with family members led to screening
of at least 30 relatives and identiﬁcation of 13 additional carriers. Non-carriers did
not report inappropriate actions, such as foregoing cancer screening. All but one
of the 32 mutation-positive participants appreciated learning their BRCA mutation
status.
Conclusions. Direct access to BRCA mutation tests, considered a model for
high-risk actionable genetic tests of proven clinical utility, provided clear
beneﬁts to participants. The unexpected information demonstrated a cascade
eVect as relatives of newly identiﬁed carriers also sought testing and more
mutation carriers were identiﬁed. Given the absence of evidence for serious
emotional distress or inappropriate actions in this subset of mutation-positive
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INTRODUCTION
Direct-to-consumer (DTC) genetic health information ﬁrst became available in 2007
when three companies started oVering microarray-based genotyping of genome-wide
single-nucleotide variants (23andMe; DeCodeMe; Navigenics). At present, health reports
provided online to consumers include heterogeneous risk information based on results
of published genome-wide association studies of distinct populations, carrier status for
known Mendelian recessive disorders, variants aVecting drug response and sensitivity to
sideeVects,andafewrarehigh-impactMendeliandominantmutationswithdisease-onset
laterinlife(e.g.23andMe,DeCODEGenetics;PathwayGenomics).
Concerns expressed in a large body of literature and position statements issued by
professional societies postulate that high-impact genetic information should not be
disseminated DTC because consumers will not be able to understand the meaning, or will
misunderstandit;positivetestresultscouldcausepanicandinappropriateactions,possibly
puttingundueburdenonthehealthcaresystem;andnegativetestresultscouldcausefalse
reassurance and inappropriate actions such as foregoing recommended cancer screening
(Berliner & Fay, 2007; American College of Medical Genetics, 2008; McGuire & Burke,
2008; Annes, Giovanni & Murray, 2010; Robson et al., 2010; Skirton et al., 2012). Very few
publishedstudieshaveaddressedthevalidityoftheseclaims.Blossandcolleaguesenrolled
participantsinaresearchstudytoassessreactionstoresultsandsubsequentactionstaken,
such as medical consultations and lifestyle changes (Bloss, Schork & Topol, 2011). Their
study found little positive or negative eVect of gaining access to this information. The
panel of tests, however, was limited to low-impact single nucleotide polymorphism (SNP)
associations with unclear clinical utility. There is a single case report of psychological
distress in a woman who received a BRCA mutation report DTC that was relieved by
genetic counseling (Dohany et al., 2012). In a survey study in which DTC genetic testing
customers were asked to interpret hypothetical scenarios of type 2 diabetes and colorectal
cancerrisk,over90%understoodthemeaningcorrectly(Kaufmanetal.,2012).
This study focuses on reactions of individuals who received their own test results of
testing for three mutations that predispose one to hereditary breast and ovarian cancer
(HBOC). These mutations are most common in people with Ashkenazi Jewish (AJ)
ancestry: BRCA1 185delAG and 5382insC, BRCA2 6174delT. BRCA1 mutations confer
upon women a breast cancer risk of about 60% and an ovarian cancer risk of about 40%;
BRCA2 mutations confer a breast cancer risk of about 50% and an ovarian cancer risk
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availableDTC,BRCAmutationtestingcanbeconsideredthemostactionablewithproven
clinicalutility(Domcheketal.,2010).
Growing activity in the area of whole genome and exome sequencing has raised the
question of how to deal with unexpected medically relevant information (Berg, Khoury &
Evans, 2011). There was some but not complete concordance among specialists as to what
information should be returned to patients (Green et al., 2012), and a global strategy
for the categorization of genes and mutations has been proposed (Berg et al., 2012).
From the socio-ethical standpoint there are few published data to inform this discussion
(Wolfetal.,2012).Ourinterview-basedstudyaimedtocollectempiricaldataontheactual
beneﬁts and harms experienced by consumers who purchased the 23andMe Personal
Genome Service
R  that includes testing for three relatively common BRCA mutations. We
report here the actual experiences of individuals who were faced with unexpected genetic
informationthathaspersonal,medical,prognosticandfamilyhealthconsequences.
PARTICIPANTS AND METHODS
The study was approved by the external, AAHRPP-accredited Ethical & Independent
Review Services Institutional Review Board (E&I Review Document IRB-1-02.5). The
protocol involved identifying within the 23andMe database BRCA mutation-positive
customers who were at least 18 years of age, had consented to participate in research,
and had chosen to view their results within the BRCA report. Before viewing their BRCA
results, customers are encouraged to read written materials that provide information
equivalent to that included in pre-test genetic counseling (Supplemental Information).
Customers then can decide if they wish to see their results for these particular genes.
Only individuals who had agreed to that step were invited to participate in this study. A
control group of mutation-negative customers matched for age, sex and ancestry were
also selected. Eligible participants were emailed an invitation that stated: “The study
will involve a phone call about learning your results for speciﬁc tests: the three most
commonBRCAcancermutationsthatpredisposetothedevelopmentofbreastandovarian
cancer in females, and prostate cancer in males. You may or may not have one of these
mutations”.Interestedcustomersclickedonabuttontolearnmoreaboutthestudyandsee
the consent form. Those who agreed to participate were scheduled for a semi-structured
phone interview by an experienced interviewer (CD) who did not know the BRCA status
of the participants. Verbal consent was obtained from each research participant at the
beginningofthephoneinterview.
Semi-structured Interview: During the interviews, we asked all participants whether
theyhadbeenawareatthetimeofpurchasethatthe23andMePersonalGenomeService
R 
(PGS
R ) included tests for high-impact BRCA mutations. Further questions fell into
several categories: personal cancer history, family cancer history, how long they waited
to view their report and whether they recalled their results. Failure to recall the results
of the BRCA report resulted in termination of the interview. Those who remembered
their results were then asked another series of questions: a rating of emotional response
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perceptionofpersonalriskforbreast,ovarianorprostatecancer,whotheyhadsharedtheir
results with, and what actions they had taken or were planning to take. Lastly, we asked
participants to identify their ethnic background and provide a retrospective assessment of
theirexperienceofobtainingtheirBRCAresultsonline.Theinterviewguidewastestedfor
understandability and clarity by engaging several employees of 23andMe and collecting
feedback.Theinterviewerwasabletoaskfollow-upquestionstoclarifythemeaningofany
speciﬁcanswer.Theinterviewsweretaped,codedandtranscribed.Attheconclusionofthe
interviews, the BRCA mutation status of each participant was veriﬁed from the 23andMe
database.
Dataanalysis:Atotalof29themeswereidentiﬁedfromthetopicscoveredintheinterview
by the interviewer and ﬁrst author who had reviewed the transcripts. Two other authors
(AKK and BM) then independently read through and coded each transcript for the
presence or absence, and other qualitative or quantitative parameters, of each of the
identiﬁed themes. Agreement between the coders was quite high, over 95%, for the
majority of themes. Themes that had lower agreement were: anxiety, actions taken
by female relatives, perceived beneﬁts of PGS testing, and discussion with a medical
profession. The coders re-reviewed the transcripts where there were speciﬁc areas of
disagreement and then, through discussion, decided on a ﬁnal coding. The majority of
initial disagreements resulted from coder error, lack of clarity on how to code reactions or
actionstakeninresponsetopriorBRCAtesting,lackofclarityonhowtocodeactionsthat
were planned but not yet taken, and interpretation of qualiﬁed responses to the perceived
beneﬁtsoftheproduct.
RESULTS
Study population
We identiﬁed 204 BRCA1 (185delAG or 5382insC) or BRCA2 6174delT mutation carriers
(130 males and 74 females) in the 23andMe database of 114,627 customers who were at
least 18 years of age and had consented to participate in research. The male–female ratio
reﬂectsthegenderdistributionintheoverall23andMecustomerbase.Ofthe204mutation
carriers, 136 (67%), 77 men (59%) and 59 women (80%), had viewed their BRCA report
and were invited to participate in this study. In comparison, 65% of all customers in the
database had viewed their BRCA report (63% of males and 67% of females). We selected a
control group of customers who did not have one of the three BRCA mutations, matched
tothemutationcarriersbyage,sexandancestry.Fivemutation-negativeparticipantswere
unable to recall their BRCA results and therefore did not complete the full interview. Two
roundsofrecruitmentwererequiredtorecruitacomparablenumberofmutation-negative
individuals. The demographics of the ﬁnal set of individuals who completed interviews
(32mutation-positive“cases”and31mutation-negative“controls”)aredetailedinTable1.
While the control group included a few more females than males, the age range and mean
agewereverysimilar.
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Cases(n D 32) Controls(n D 31)
Females Males Females Males
Completed Interview 16 16 18 13
Age Range 30–73 26–62 27–73 23–66
Mean Age by Sex 51 43 50 43
Mean Age by Group 47 47
When you purchased the 23andMe Personal Genome Service
R  were you aware that it included testing for
mutations that predispose to breast and ovarian cancer?
Yes 7 6 10 10
No 9 10 8 3
Were you aware that having or not having Ashkenazi Jewish ancestry inﬂuences your risk of carrying one of
the three mutations 23andMe is testing for?
Yes 10 10 8 5
No 6 6 10 8
Awareness of BRCA test and ancestry-based risk
At the time of purchase, only 13=32 (41%) cases were aware that BRCA testing was
included inthe PGS
R , comparedto20=31(65%) ofcontrols (Table 1).In contrast,20=32
(63%)caseswereawarethathavingAshkenaziJewishancestryinﬂuencestheriskofhaving
oneofthethreeBRCAmutations,comparedto13=31(42%)ofcontrols.
Personal and family history of cancer
Answers to the questions regarding personal and family history of cancer are summarized
inTable2.Asexpected,morecasesthancontrolshadapersonalorfamilyhistoryofbreast
and ovarian cancer; there was little diVerence between cases and controls in terms of
personalorfamilyhistoryofprostateandothercancers.
Viewing of the BRCA report
To avoid precipitating the discovery of a BRCA mutation in people who did not already
knowabouttheirmutationstatus,weonlyinvitedcustomerstoparticipateiftheyhadcho-
sen to view their BRCA report. In the current structure of the 23andMe results-reporting
website, BRCA reports are “locked”, which means they require an additional customer
approval step to “open” (display) the result. This feature enables customers to view other
health reports before separately choosing to view the BRCA report. During the interview,
we askedabout theirrecollection ofopening thereport. Responsesshow thatone caseand
nine controls did not remember whether the BRCA report required an extra step to open,
and one case and ﬁve controls did not remember when they opened it. The majority, 24
cases(75%)and18controls(58%),however,rememberedthattheyvieweditimmediately,
as soon as it was available to them (Table 3). Seven cases and eight controls waited for
days to months before viewing their BRCA results. Reasons given for this delay included
uncertainty about wanting to know, being too busy with other tasks, and not noticing the
reportuntilsomelatertime.
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Cases(n D 32) Controls(n D 31)
Females Males Females Males
(n D 16) (n D 16) (n D 18) (n D 13)
When you purchased the 23andMe Personal Genome Service
R  – had you been diagnosed previously with
breast, ovarian or prostate cancer?
Yes
BC 2 1
BC/OC 2
PC 1
No 12 16 17 12
Had you been diagnosed previously with any other cancer?
Yes
Testicular 1
Melanoma 1
Sarcoma 1
No 16 13 17 12
Had a ﬁrst or second degree relative been diagnosed previously with breast or ovarian cancer?
Yes
BC 10 9 6 6
OC 6 5 1
No 5 4 11 5
Had a ﬁrst or second degree relative been diagnosed previously with any other cancer?
Prostate 0 4 5 4
Pancreatic 1 2 1
Colon 1 1 2
Gastric 1 1 1
Melanoma 2
Lung 2 1
Other uterine(1) bladder(1) esophageal(1) leukemia(1)
lymphoma(1)
Notes.
BC – breast cancer; OC – ovarian cancer; PC – prostate cancer.
Recollection of the BRCA test results
The blinded interviewer asked participants whether they remembered their BRCA results
and what they learned from them. Five individuals did not remember their results and
wereexcludedfromfurtherparticipationinthestudy.Alloftheseweremutation-negative.
Eleven women and 14 men stated that they learned for the ﬁrst time that they had a
mutation in either BRCA1 (n D 10) or BRCA2 (n D 15). Seven participants (ﬁve females
and two males) knew prior to obtaining their results that they carried one of the three
BRCA mutations that are tested for as part of the PGS
R . Conﬁrmation of their carrier
status by the PGS
R  increased their conﬁdence in 23andMe test results and encouraged
some to initiate testing of their relatives who they understood might also be carriers.
Reasons for prior BRCA testing included a diagnosis of breast and/or ovarian cancer
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Cases(n D 32) Controls(n D 31)
Females Males Females Males
(n D 16) (n D 16) (n D 18) (n D 13)
Was your BRCA report locked?
Yes 14 15 11 9
No 1 1 1
Do not remember 1 6 3
When did you unlock it?
Immediately 11 13 11 7
Later 4 3 6 2
Do not remember 1 1 4
What did you learn from your results?
I learned for the ﬁrst time that I am a carrier of a
BRCA1 or BRCA2 mutation
11 14
I had previous testing for these mutation and
already knew that I am positive
5 2
What was the reason for previous testing?
I was diagnosed with breast or ovarian cancer 3
A close female relative with breast or ovarian cancer
tested positive for one of these mutations
1 1
A close female relative with breast or ovarian cancer 1 1
I learned for the ﬁrst time that I am NOT a carrier of
a BRCA1 or BRCA2 mutation
18 13
(three women), or having a ﬁrst-degree relative with breast and/or ovarian cancer – with
andwithoutaknownBRCAmutation(twomenandtwowomen)(Table3).
All participants in the control group recalled their negative mutation status correctly.
None of the mutation-negative individuals had been tested previously, they ﬁrst learned
thisinformationthroughthePGS
R  testing.Mutationstatusasrecalledbyeachparticipant
wasindependentlyconﬁrmedthroughinspectionofthedatabase.
Emotional responses to BRCA test results
Participants were asked about their initial emotional responses to seeing their 23andMe
BRCA results. They were asked if they felt surprised by their results, and why or why not
(Table 4). Ten mutation-positive individuals (six women and four men) who expressed
surprise referenced the lack of a family history of breast or ovarian cancer or presence
of only sporadic late-onset breast cancer, “not the genetic type”. Others were surprised
becausetheybelievedthefrequencyofthesemutationstobelowinthegeneralpopulation.
Ten of the mutation-positive women were not surprised, including the ﬁve who had
been previously tested, one who had close relatives known to be mutation-positive, and
four others with a strong family history. The 12 mutation-positive men who were not
surprisedcitedthefollowingasreasons:twoalreadyknewabouttheirmutation,onehada
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Cases(n D 32) Controls(n D 31)
Females Males Females Males
(n D 16) (n D 16) (n D 18) (n D 13)
Were you surprised by this result?
Yes 6 4 1 0
No 10 12 17 13
How did you feel about this information?
Extremely upset (cried, lost sleep, had thoughts of
suicide...)
0 0 0 0
Moderately upset (couldn’t stop thinking about the
result, felt moderate anxiety)
3 1 0 0
Somewhat upset (initial disappointment, felt
anxious at ﬁrst but then anxiety went away)
3 6 0 0
Neutral 9 8 7 8
Relieved 1 1 10 5
Extremely relieved (if had high anxiety before) 0 0 1 0
mutation-positiveaunt,somehadapositivefamilyhistoryofbreastand/orovariancancer
andothershadrealizedtheywereatriskbyhavingAshkenaziJewishancestry.
Participants were read six options (which overlapped the Impact of Events Scale) and
asked to choose which emotional response best ﬁt how they felt at the time of receiving
their results (Table 4). For the mutation-positive group, remarkably, none of the 32
reported having been “extremely upset”. Three of the four who were “moderately upset”
were also “surprised” or “shocked” by discovering that they carried a BRCA mutation.
The nine participants who said they had been “somewhat upset” initially, with anxiety
subsequentlysubsiding,includethreewhowerealso“surprised”.Remarkably,ninewomen
and eight men who were mutation positive reported feeling “neutral”. Of these 17, four
women and two men already knew that they were BRCA mutation carriers. One female
carrier was “relieved” to get conﬁrmation of her previously known result. One young
womanwhowasnot“surprised”andfelt“neutral”said:
“I wasn’t surprised. It didn’t come as a surprise and, like I said, it wasn’t scary to me and it
wasn’t bad news. It was just kind of more information to work with I guess. Yeah. I think I’m
the only person in my family who’s had this testing so far. And I maybe would have diVerent
feelings about my results if, you know, I lost my mother to breast cancer, if it was a more
emotionally charged thing, or if I knew somebody else who had it or something like that. I
think it would maybe feel diVerently, but as far as I know I’m the only person whose been
tested for it”.
One male who learned about his carrier status for the ﬁrst time reported feeling
“relieved” because his daughter who was tested simultaneously by 23andMe had not
inheritedhismutation.
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surprised”; she also felt “extremely relieved” because she had a family history of breast,
prostate and pancreatic cancer. The remaining 30 did not report feeling surprised, despite
the fact that 12 had a family history of breast cancer in a ﬁrst or second degree relative
and one had a family history of ovarian cancer (Table 2). The emotional responses they
identiﬁed most with were “neutral” or “relieved” (48% in each category), with 66% of the
“relieved”respondersbeingfemale(Table4).
Effect of BRCA test results on perception of cancer risk
We explored whether knowing one’s BRCA status aVected the perception of one’s own
breast and ovarian cancer risk (for women) or breast and prostate cancer risk (for men).
Most female carriers reported understanding their personal risk as signiﬁcantly elevated,
and several correctly recited the risk ﬁgures that they had learned from their 23andMe
report for both cancers. Some stated that their perception had not changed much because
theyhadalwaysbelievedtheywereathighriskduetobreast/ovariancancerinclosefamily
members and Ashkenazi Jewish ancestry, but that knowing they had inherited a BRCA
mutation made them more aware of the reality and prompted them to take action. In
general,malemutationcarriersperceivedtheirpersonalriskforbreastcancertobelowand
theirriskforprostatecancertobeslightlyhigherthanaverage.
The majority of BRCA mutation-negative participants stated that they perceived
their cancer risk to be unchanged; only one woman thought her risk was reduced. The
majority said they felt relieved not to be at high risk but realized that other genetic
factors and environmental factors can still cause them to develop breast or ovarian
cancer. Several women expressed the understanding that only the three common BRCA
mutations were included in this test and that other mutations in these genes may still be
present. Some mentioned that they had a slightly higher than average risk based on their
separate23andMebreastcancerreportcoveringsevenvariantsinothergenesknowntobe
associated with breast cancer, further conveying their understanding that there are many
other risk factors to consider beyond BRCA mutations. Not a single mutation-negative
participantinterpretedthenegativeBRCAtestresultasindicatingnoorsigniﬁcantlylower
thanaverageriskforthesecancers.
Sharing of BRCA test results
We asked participants with whom they shared their BRCA results. The majority of
mutation-positive participants shared their results with spouses/partners and blood
relatives (Table 5). In addition, 50% (8 females, 8 males) shared their test results with
friends, ranging from “a few friends” to “everybody”, which included using blogs or social
media. Of the 32 mutation-positive participants, only two men had not yet shared it with
anyone but said they were planning to share it with present or future spouses and other
familymembers“asappropriate”.
Themajorityofmutation-negativeparticipantssharedtheirBRCAresultswithspouses
and family members, and some (7=31) shared with friends or medical care providers. The
Francke et al. (2013), PeerJ, DOI 10.7717/peerj.8 9/24Table5 Sharing of BRCA Results.
Cases(n D 32) Controls(n D 31)
Females Males Females Males
(n D 16) (n D 16) (n D 18) (n D 13)
With whom have you shared information about your 23andMe BRCA test results?
Spouse 9 8 5 8
Other relatives
Mother 4 6 5 3
Aunt(s) 5 3 2
Sister(s) 7 7 4 2
Daughter(s) 3 3 1
Father 1
Brother 1 1
Son 3 1
Cousin(s) 4 1 1
Niece(s) 1
Grandmother 1
Stepmother 1 1
Sister-in-law 1
Friends 8 8 5 2
Primary care physician 4 5 5 2
OB/GYN physician 5 1
Oncologist 4 1
Genetic counselor 5 1
Cancer geneticist 2
Medical geneticist 1
Other person 2
Nobody 2 8 4
remaining12=31(39%)didnot sharetheirresult withanyone,statingthat theydidn’tfeel
ittoberelevant(Table5).
Communications with health care providers
Seven mutation-negative participants said they informed their primary care physician.
Thirteen of the 16 mutation-positive women (including two who had previously
tested positive) sought medical advice (most did so immediately) from their primary
care physician, gynecologist or oncologist. Five consulted with a genetic counselor,
usually upon referral from the primary care physician, who then coordinated repeat
BRCA testing in a clinical lab (in most but not all cases) and referred them to an
oncologist.
Overall, our interviews revealed that sharing of BRCA test results with physicians
was more common amongst mutation-positive individuals (19=32 or 60%) than
mutation-negative ones (8=31 or 26%), and within the mutation-positive group, it was
also more common amongst women (13=16 or 81%) than men (6=16 or 38%). The three
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wereBRCAmutation-positiveandhadbeentreatedforbreastand/orovariancancer.
The rate at which mutation-negative participants shared their results with physicians is
comparable to those reported in larger surveys of DTC customers: 27% (Bloss, Schork &
Topol, 2011) and 20% (Kaufman et al., 2012). The high level of sharing with physicians for
themutation-positivewomenmostlikelyreﬂectstheactionabilityofthetestresults.
Some female mutation-carriers expressed feeling pressured into surgical procedures
by physicians, and some stated that the full range of choices presented to them by genetic
counselorshadcausedanxiety.
“It was a real shake up for me for a little while. But not because of my reaction to the BRCA2
results from 23andMe, but to the total fear factor that was put in by all of the traditional
medical people; based on my doctor telling me if I didn’t get my breasts and my whole female
organs out within 6 weeks, and by the way that date has long since passed.”
“At the beginning I was not anxious. It was very rational, you know, it is what it is. Later I
had slight anxiety, because there are so many choices. So if it had been like so okay, this is,
you know, one way to do the surgery, that’s ﬁne. But then I went to the genetic counselor, it’s
like so many choices, and whenever you have choices you have anxiety, because it’s time to
research and make right decisions and so on.”
Although only a few mutation-negative females shared their results with physicians,
thosethatdidsofelttheirphysicianshowedlittleinterest,didnotknowwhattodowiththe
informationordoubtedthevalidity.
“I gave a full printout of my results to my primary care physician, just for the heck of it. But it
really didn’t come up in conversation. I didn’t really talk about it. I didn’t think I was at risk
because it conﬁrmed like, oh, I’m not at risk and that was that.”
“I enabled my surgeon and my internist both to have access to the information that I received
from 23andMe. But I think essentially their feeling was that it wasn’t really helpful you know
that it was purely a survey. It didn’t provide the type of genetic information that they would
ﬁnd extremely helpful.”
“I shared the results with my physician when I did have the mammogram. She kind of looked
at me like physicians don’t know how to handle this information because that’s not part of
their routine. So I don’t know if she took it in and goes – okay I don’t know what to do with
this, I’m gonna go with what I know [that] is order a mammogram.”
“And I was telling my doctor about this. And I said I had this analysis and it showed diVerent
likelihood of this and that. I didn’t mention the breast one because it was never a concern.
And he said how much did it cost, and I said I think it was $150 a year or something like that.
And he said ‘Well, how can they have good results for only that much?’ And I said they do.
They really do a very careful analysis and they’re constantly bringing new results. So he wants
to see it sometime, so I’ll have to print it out because he’s open to it”.
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Cases(n D 32)
Females Males
(n D 16) (n D 16)
What did you do next?
Talk to family/friends 7 7
Consult my primary care doctor 4 1
Consult a genetic counselor 3
Consult a cancer specialist (OB/GYN, oncologist) 6
Consult a cancer geneticist 2
Repeat BRCA testing in a clinical lab 3 2
Had physical breast/ovarian exam and breast imaging 5
Had risk-reducing mastectomy 1
Had risk-reducing oophorectomy (removal of ovaries) 2
Did online research 1 2
Quit smoking, changed diet 1
What are you planning to do in the future?
Will have regular breast/prostate cancer surveillance screening 7 13
Will have risk-reducing mastectomy 3
Will have risk-reducing oophorectomy 4
Will make sure my mother/sisters/daughters/brothers/sons get
tested
12 5
Will mention BRCA results to physicians 2
Will ask oncologist for prophylactic drug treatment 1
Will recommit to staying healthy 1
Will stay updated on breast cancer research 1
Actions taken or planned in response to BRCA report
Mutation-positive participants were asked about the immediate next steps they took
after learning their results and what they were planning to do in the future (Table 6).
In terms of immediate action, sharing results with family and friends was the most
common response. The majority of women also sought medical advice. Prior to being
tested by 23andMe, three women had been diagnosed with breast cancer and had
undergonemastectomiesandonehadalsoundergoneaprophylacticoophorectomy.There
were 11 mutation-positive women who received this information through 23andMe for
theﬁrsttime.Amongthese11womenthefollowingactionsweretakenorareplanned:one
prophylactic mastectomy, three planned mastectomies, three oophorectomies, and four
plannedoophorectomies(afterchildbearing).Fivesaidtheywenttohavebreastexamsand
breastimagingaftergettingtheirresults,andthesevenwhoneitherhadnorwereplanning
to have mastectomies reported that they would continue to have regular breast cancer
monitoring(Table6).
In general, male carriers did not initially consult a physician; several stated that they
were familiar with the literature, had done online research and/or were working as
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(81%), said they would seek or would continue to have regular breast and prostate cancer
screening.
“It’s a little bit interesting as a male approaching this, because I can’t quite put myself in the
female perspective. But the combinations of prophylactic type procedures that are available
for a female with these results are very, very diVerent than what’s available to me. So, no, I
don’t have anything directly planned other than just to be aware.”
“Breast cancer, yeah, fairly low. I know it’s possible, but it’s not particularly common. I mean,
I don’t know if the studies have been linked strongly with prostate cancer, but it follows in my
family directly. So that’s the one I’ve been thinking about.”
“I might start my prostate cancer screening earlier, maybe at 45 or 40 even. I might tell my
physician I have this gene and that it might be a good idea to get tested younger than the
recommended age.”
The present study reveals that for those who received a positive BRCA test result from
23andMe,therewasadistinctlypositiveeVectofidentifyingadditionalfamilymembersat
risk.
We observed a signiﬁcant expansion in identiﬁcation of BRCA carriers through testing
ofrelativesofbothfemaleandmalemutationcarriers.
Malecarrier:“My mother saw a genetic counselor as a result of my testing and my little sister
saw a genetic counselor as a result of my test.”
At the time of our interviews, 30 secondary (family member) BRCA tests had been
carried out as a result of the initial testing, either through physician channels or through
23andMe, with 13 positive and 17 negative results. In one of these mutation-positive
secondary cases, early breast cancer (DCIS) was discovered by MRI, a sensitive imaging
procedure usually oVered as a screening test only to mutation-positive women (Robson &
OYt, 2007). Several secondary cases with mutation-positive BRCA tests also underwent
prophylacticmastectomyandoophorectomyandothersindicatedthattheywereplanning
tohavebothrisk-reducingproceduresinthefuture.
In retrospect: Perceived beneﬁts outweigh harms
At the end of the interview, we asked participants whether they thought purchasing the
PGS
R  was worth it, whether they would do it again, and why or why not. 30=32 cases and
30=31 controls said they would do it again. The participants found the PGS
R  worthwhile
for several reasons; the most signiﬁcant being that some mutation carriers felt it may have
savedtheirlivesorthelivesofrelativeswhotestedBRCApositiveasaresultoftheprimary
participantbeingtested.Inaddition,participantsreceivedhealthinformationunrelatedto
BRCA that they found useful for personal risk assessments or family planning, or thought
the PGS was worthwhile because they discovered or conﬁrmed their ancestry, or just had
theircuriositysatisﬁed.
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Female carrier: “While the results were shocking and a little stressful, ultimately I think this
could potentially change my life, and it obviously made a diVerence for my aunt, who was
able to catch pre-cancer early. So I think all in all, it’s a positive thing. We would have never
known, because there are no [aVected] ﬁrst and second-degree relatives. So until somebody
ended up with breast or ovarian cancer I don’t think we would have known. This way we’re
taking care of things prophylacticly.”
Femalecarrier:“Well, I got information that I could do something about. That’s what I’m
telling people. You know, if you get information that you can do something about, and I think
particularly Ashkenazi Jewish women, it’s certainly worth doing. I mean if someone did say
to me ‘I don’t know what I would do with the information if I had that information,’ but I’m
a proactive person, so it’s hard to imagine someone not doing something.”
Male carrier: “Even after I talked with genetic counselors, they never would have recom-
mended me to be tested based on my family history that I knew of at the time. I feel like a
genetic secret was found in my family. I feel like I may have saved my sister’s life. I mean,
nobody knows. That’s a hard thing in our family because nobody had cancer early, but it
makes a diVerence. You accept it. It’s in your system and I’m lucky enough to know that it’s
there as opposed to ﬁnding out something too late. It increases your odds you’re going to ﬁnd
something and ﬁnd it earlier.”
Male carrier: “I immediately had my children tested, ﬁnding that my daughter was
predisposed (sic) to BRCA1 and she’s now being treated because of this. In other words,
23andMe may very well have saved my daughter’s life. My doctor and we have spoken to
many, many of our friends to tell them about what we think about 23andMe. It’s all positive.
I bet we’ve told 150 people.”
Male carrier: “Well, ﬁrst oV, speciﬁcally for this issue of the BRCA thing, it provided me
information. We had cancer in the family. We had reason to wonder and it solved it very
clearly relating to my daughter. I don’t think that learning that I have a few percentile or
lower risk of anything is going to change my life, but some things are interesting, some things
are informative and I think it’s important.”
Male carrier: “I think it’s good to know these things, regardless of whether it’s something
you can control or do something about. In the case of this particular mutation, there’s only a
50% chance that if we had a daughter she would inherit the same gene. And maybe I would
want – knowing now that I am a carrier – I would want, if we have a daughter, I would want
her to get genetic screening. I think it’s a good thing.”
Male carrier: “And as healthcare becomes more and more streamlined and more speciﬁc,
or I don’t know exactly what the word I’m looking for there is, but as it becomes more treat-
ment focused that you need to be aware as possible of what your health situation is and what
your risks are, because you can’t expect the healthcare provider to have all that information.
You need to have your information, as much information as possible to make good decisions.”
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Only one of the 63 participants reported a negative impact. This participant was a
mutation-positive man with a family history of breast cancer. He reported “emotional
cost”andsaidhewouldprefernottoknowhismutationstatus.
“I would not do it again, because it is really not information I need to know. I don’t think the
cost in dollars was important, I think the emotional cost is more. The impact of the results to
a greater extent was negative. It’s just basically knowing that I have it, I might pass it on. And
that’s the main thing. Sometimes ignorance is better.”
In addition, one other case and one control said they would not purchase the 23andMe
PGS
R  again. One woman already knew that she was positive for the BRCA mutation and
had had a double mastectomy in the past; therefore, she felt that her PGS
R  result did not
providehernewinformation.Themutation-negativeparticipantwhowouldnotpurchase
the PGS again had received the kit as a gift and reported prior emotional instability as a
reasonforherpreferringnottoknow:
“I guess denial is a pretty powerful feeling, and sometimes not knowing something helps you
just forage through life without having some details that might cloud the way you perceive
things. And so I guess a little bit of rosy-colored glasses would help someone like myself. I guess
I don’t want to think negatively. Even if it were the truth, I might choose not to know that.”
Impact on male carriers
Many male carriers expressed strong concern about the risk of passing on a BRCA
mutation to their daughters. Despite the fact that female carriers have the same risk
of passing on the mutation, they did not mention this as a major concern since they
were primarily focused on their own risk for disease and on making decisions about
risk-reducingprocedures.
Interviewquotesfrommalecarriers:
“I was never concerned for myself, even though when I found out, the ﬁrst thing that came to
my mind was: will my daughter carry this. So I was extremely concerned but not for me, if I
answer extremely concerned, it wasn’t for me at all, but if you’re asking what my emotion was
it was extreme concern, but not over my own situation.”
“I do see that I have a little chance of getting breast cancer even though I’m a male, and it’s
probably increased in males with BRCA1 compared to normal males, but that is a very low
chance. So I’m not worried about myself. I might be a little worried if I get married and have
children, because it has 50% chance of passing on, and if the child is a female then she has a
high risk.... initially my thought was I shouldn’t have children.”
“For breast cancer, I guess being a male the statistics are not so dramatic about that, what I
read on your site about it. So as far as my health is concerned, and I can also compare to my
father and grandfather who must have had the mutation, I’m at some risk to die sometime
from something but it’s not really an anxiety factor. I would have been alarmed had I learned
that my daughter had it, but I guess luckily she doesn’t.”
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We scrutinized the interview transcripts for any evidence of misunderstanding of the
information provided in the online BRCA report. One female mutation carrier was under
the impression that all 23andMe health reports deal solely with disease probabilities, and
did not appreciate that BRCA mutation testing provides a deﬁnitive answer about carrier
status.
“I really read it as what it basically is. It’s not that I necessarily am a carrier. I’m just you
know statistically it’s likely that I could be.” This participant was also confused about the
mode of inheritance: “I have 5 children and 3 of them are daughters. Well it doesn’t matter
because it’s gonna be passed through the boy.”
She had described her initial response as “surprised”, because her mother who had
breast cancer was not Jewish, and her emotional reaction as “neutral”. She subsequently
consultedwithherphysicianandreceivedpost-testgeneticcounselingwhichshedescribed
asextremelyupsettingandwhichdidnotalleviatehermisunderstanding.
Two mutation-positive participants interpreted the fact that the BRCA report was
initially “locked”, requiring an extra click to opt-in to view the report, as indicating a
positiveresult:
“When you put a locked result on and you say this is locked, you don’t have to open it, well,
everybody knows what that means. As soon as you say this result is locked and you can click
here if you want to open it, you know it’s going to say something not good.”
“As soon as I saw it was locked, I opened it right away ‘cause I knew what it was. I mean there
was no reason it was gonna be locked unless it was a mutation.”
Therewasnoevidenceamongthemutation-negativegroupthatanyoftheminterpreted
theirdatatosuggestasigniﬁcantreductioninbreastcancerrisk.Allbutonereportedtheir
perception of their own risk for breast and ovarian cancer to be unchanged after learning
abouttheirBRCAmutation-negativestatus.
DISCUSSION
ThedatareportedhereclearlydemonstratethatprovidingBRCAmutationresultsdirectly
to consumers beneﬁted a large fraction of individuals. A number of women without a
familyhistoryofearlyonsetbreastorovariancancerdiscoveredthattheycarryaBRCA1or
BRCA2mutationthatconveysahighrisk.Inmanyfamilies,thesebeneﬁtswereextendedto
relatives of male or female mutation-positive study participants who took the initiative to
bescreenedafterlearningofthe23andMecustomer’sresultandtestedpositive.Newfound
awareness of their high risk led the majority of these women to seek medical advice
and many took or are planning to take risk-reducing actions upon the advice of their
physicians.
None of our 32 mutation-carrying study participants reported serious emotional
disturbance such as feeling extremely upset, suicidal or requiring professional psychiatric
helpafterlearningoftheirmutationstatus.Fourmutationcarriersreportedthattheywere
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Emotionaldistressshortlyafterlearningsigniﬁcantgeneticinformationisnotunexpected,
but decreases over time, as reported in a meta-analysis of women who had undergone
BRCA mutation testing within the healthcare system (Hamilton, Lobel & Moyer, 2009).
Thereisgreaterconcernoveremotionaldisturbancethatismoresevereandlastsforweeks,
months or years. We did not obtain reports of long-term emotional disturbance. Only
one of 32 mutation-positive individuals, a male, regretted obtaining his mutation status.
In contrast to expectations, half of the mutation-positive participants of either gender
describedtheiremotionalresponseasneutral.
Our results are comparable to those of a study on the disclosure of APOE genotypes
to adult children of patients with Alzheimer disease (AD) that measured symptoms
of anxiety, depression and test-related distress (Green et al. REVEAL study, 2009). In
contrast to our study of DTC customers who received unexpected results, the REVEAL
study compared disclosure and nondisclosure groups of participants (that both were
pre-screened and underwent extensive pre-test counseling and post-test psychological
follow up) and failed to ﬁnd signiﬁcant diVerences in test-related distress. This is even
more remarkable given the current lack of preventive measures for AD in contrast to the
preventiveoptionsavailabletoBRCA1orBRCA2mutationcarriers.
The majority of participants shared their BRCA results with family and friends, and
all female carriers consulted with health care providers and were guided to appro-
priate actions such as more frequent monitoring or risk-reducing mastectomy and/or
salpingo-oophorectomy. A large prospective multi-center cohort study has demonstrated
the eVectiveness of these procedures in BRCA mutation carriers for lowering the risk of
breast and ovarian cancer and reducing cancer-speciﬁc mortality and all-cause mortality
(Domcheketal.,2010).
Female mutation-positive participants with a personal or family history of
breast/ovarian cancer were more aware of their risk prior to 23andMe testing, and ﬁve
hadreceivedBRACAnalysis
R  testingpreviously.Incontrast,wheretheprimarymutation-
positiveindividualidentiﬁedthrough23andMewasmaleorthemutationwastransmitted
throughthemaleline,thereusuallywasnofamilyhistoryofbreast/ovariancancerandthe
identiﬁcation of a BRCA mutation came as a complete surprise. The female members of
these families were not eligible for BRCA testing within the healthcare system and, in the
absence of population-wide screening for these mutations, they would not have known
abouttheirincreasedcancerrisk.Wedonotknowtheﬁnaltallyofﬁrst-andsecond-degree
relatives who were tested because of the primary customers’ positive BRCA test results;
30 were known at the time of the interviews. Several of the 13 secondary cases who tested
positive had undergone or planned to have risk-reducing surgical procedures. Major
eVects on family members were also reported for the single case studied by Dohany et al.
(2012). A population-based study from Denmark reported on uptake and timing of risk-
reducing surgery in 306 healthy BRCA carriers with no personal history of ovarian and
breast cancer. The 10-year uptake was 75% for salpingo-oophorectomy and 50% for
mastectomy (Skytte et al., 2010). In a prospective study conducted in Washington DC,
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both risk-reducing procedures (Schwartz et al., 2012). It is worth noting that for younger
womenthediscoveryofaBRCAmutationcanleadtodiYcultdecisionsaboutconsidering
risk-reducing surgery in the face of uncertainties about the eVectiveness of screening
procedures(MRIversusmammography)andcancauseconsiderableanxiety.
While some mutation-positive female customers crusaded within their extended
families with missionary zeal, others, most often males, felt a considerable burden at
having to inform their at-risk relatives. One was distressed after being told by a genetic
counselor that informing relatives was his duty, and another asked us for a guidance
documentthatwouldtellhimhowbesttoconveythatinformation.Inasystematicreview
ofqualitativestudiesoncommunicationofinheritedcancerrisktoat-riskrelatives,Chivers
et al. (2010) identiﬁed themes that facilitate or inhibit such interactions, such as tension
between the duty to inform and the wish not to harm or distress the recipients of the
information; for BRCA mutations, speciﬁcally, carriers were uncertain about whether
and how to inform male relatives and they desired health professionals’ input. The
burden of the role of informant has been well illustrated by the bioinformatician
Manuel Corpas who was managing the 23andMe accounts of his extended family
(Corpas,2011;Corpas,2012).
While male BRCA carriers responded positively by adhering to recommended prostate
cancer surveillance or starting it at an earlier age, the 50% chance of passing on the
mutation to their children caused many of them considerable emotional distress. In
current medical practice, children under age 18 are not tested for adult-onset genetic
diseases that lack preventive treatment options during childhood. 23andMe enables the
testingofchildren,withparentsbecomingthecustodianoftheinformation.Asarticulated
by several study participants, this opportunity to have their children tested shifted their
burden from anxiety over not knowing whether they passed on the mutation to relief if
they didn’t, or if they did, to facing the decision of when and how to inform their carrier
children.
One indirect way that we assessed the extent of harm to participants who chose to
view their BRCA test results was by asking them if they would purchase the service again.
Only one female non-carrier, who had obtained the PGS
R  as a gift, and one male carrier,
stated that they would prefer not to know their result. The male cited distress about
genetic risk for his future daughters as the reason. A previous small study of predictive
testing for BRCA mutations in males from mutation-positive breast cancer families
reported that concern about transmitting increased cancer risk to daughters was the
major motivating factor for testing. In that study, four of 18 males who tested positive
hadadverseresponses,withthreerefusingtodisclosethetestresultstotheirfamilyandone
regretting his participation (Daly et al., 2003). In another study, none of the parents,
including men, found it diYcult to inform their adult children of their BRCA mutation
(Hallowelletal.,2005).
With respect to misunderstanding BRCA test results, we identiﬁed one female
participant who reported confusion about the meaning; she had also sought genetic
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addedtoherdistress.
Remarkably, none of the male mutation carriers interpreted their results as having no
relevance to their female relatives. The BRCA report in the 23andMe PGS clearly states:
“Their own risk aside, it is important for men to know whether they are carriers of BRCA
mutations because they have a 50% chance of passing the mutation on to their daughters,
who would then be at increased risk for breast and ovarian cancer. The mothers and sisters of
men who carry one of these mutations also have a 50% chance of being carriers”.Incontrast,
the literature suggests widespread misperception about paternal transmission of breast
cancer risk. Many women and their physicians underestimated the signiﬁcance of a family
history of breast cancer on the father’s side of the family (Metcalfe et al., 2010). In that
study, only 34% of 273 women with early-onset breast cancer knew that a father can pass
anabnormalbreastcancergenetohisdaughter,comparableto29%of628Swissphysicians
surveyed by Pichert et al. (2003). 23andMe regularly updates its reports in order to
maximizethechancethatcustomersunderstandthosereportsandtheconceptsunderlying
those reports. Although genetics education is a mission of a broad array of stakeholders,
DTC personal genomics companies are in a unique position to provide such educational
materials. In our experience, consumers appear more likely to read and learn about an
unfamiliar topic such as genetics when the information is personalized. The responses
of physicians to the BRCA DTC results were distinctly diVerent for women with positive
and negative results. Physicians reacted to positive results with appropriate referrals to
genetic counselors, requesting conﬁrmation of BRCA results in another lab (all of those
were conﬁrmed) and referrals to oncologists for treatment. Few of the BRCA-negative
individuals shared their BRCA reports with physicians and found them unhelpful; their
physiciansdidnotknowwhattodowiththereportsanddidnotappreciatethevalueofthe
information.
Our study has several limitations. In conducting it, we relied on volunteers willing to
share their experiences. The emotional responses reported by the 16 men and 16 women
who are BRCA carriers and agreed to be interviewed for this study may diVer from those
experienced by the 61 male and 43 female mutation – positive individuals who did not
reply to our invitation. Customers of 23andMe are also not entirely representative of
the overall population, and the participants in this study may represent a pro-active
more scientiﬁcally educated group, although no data on educational background were
collected as part of this study. We cannot exclude that somebody who had a traumatic
response may not have wished to revisit that experience in an interview. However, the
initial study participation rate was higher within the mutation-positive group than within
the mutation-negative group. In addition, not a single instance of serious adversereaction
has been brought to our attention either through this project or other projects. The case
reported by Dohany et al. (2012) represents a customer who initially experienced distress
and successfully made use of the post-test genetic counseling that is recommended in all
23andMe reports for those who may require it. Furthermore, as the time interval between
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theaccuracyofrecollectionsmayhavediVeredamongparticipants.
Current practice guidelines, and insurance reimbursement, limit BRCA mutation
testing to women with early onset breast or ovarian cancer and their ﬁrst degree female
relatives, as well as to close relatives of mutation-positive index cases (Robson, 2003). This
policy missed the BRCA mutation status of Jill Steinberg, whose sister and mother had
early onset breast cancer but were BRCA mutation negative. Jill discovered her mutation
through 23andme PGS
R  and found that she had inherited it from her father who had
prostatecancer(Saunders,Nazareth&Pressman,2011;Steinberg,2011).
When unselected Jewish women in Canada were screened for these three founder
mutations,themutationprevalencewasreportedas0.5%forBRCA1and0.6%forBRCA2
(Metcalfe et al., 2010). Within two years after learning of their BRCA mutation, 11.1% of
women had undergone prophylactic mastectomy and 89.5% prophylactic oophorectomy;
and those who had these procedures reported reduced distress (Metcalfe et al., 2012).
Given the frequency of these three mutations in the Ashkenazi Jewish population, a
population-wide screening program has been proposed (Metcalfe et al., 2012). When
considering the target population for such a screening program, it is important to realize
that in our study six cases and six controls self-identiﬁed as non-Jewish, and one control
as Jewish non-Ashkenazi (Table S1). One of the controls was adopted with unknown
biological parents. The other cases and controls who identiﬁed as Caucasian non-Jewish
reported Eastern European ancestry, except for one mutation carrier who self-identiﬁed
as East Indian. His BRCA1 185delAG mutation has been previously identiﬁed in breast
cancer patients in India (Vaidyanathan et al., 2009), as well as in breast/ovarian cancer
families with Sephardic Jewish ancestry in Spain (D´ ıez et al., 1999) and in descendents
of early Spanish settlers in Colorado (Mullineaux et al., 2003). Therefore, limitation
of testing for these three mutations to people who identify as Ashkenazi, could miss
BRCA1 185delAG carriers with Sephardic Jewish ancestry. On the other hand, BRCA1
or BRCA2 mutations besides the three most common ones have also been reported in
Ashkenazi Jewish women with breast/ovarian cancer although at much lower frequencies
(KauVetal.,2002).
Outcome studies of relatives of BRCA mutation carriers provided strong evidence
that carrier identiﬁcation is beneﬁcial with high uptake of risk-reducing procedures and
reducedcancerriskandcancer-speciﬁcmortality(Skytteetal.,2010;Domcheketal.,2010).
Given the high rates of appropriate medical follow-up for the individuals and their family
members, the absence of signiﬁcant emotional distress and reports of inappropriate
follow-up, and the ethnic diversity of the mutation carriers, our data support the
establishment of population-based screening programs for these three relatively common
mutations.
With the frequency of genome/exome sequencing studies increasing rapidly, the
discussion of how to deal with unexpected medically relevant data is currently at the
forefront (Berg, Khoury & Evans, 2011; Berg et al., 2012; Green et al., 2012), with little
published empiric data to guide it (Wolf et al., 2012). Most of the information that is
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the risk of common diseases or variants of unknown signiﬁcance. In contrast, BRCA
mutations represent the group of highly penetrant autosomal dominant neoplastic
disorders with available management options. Incidental discovery of such mutations
engenders a diVerent set of responsibilites and diYcult choices for patients and their
relatives. In our study, 25 individuals who did not know they were carrying a BRCA
mutationweregivenunexpectedandpotentiallylife-savinginformationand30additional
relatives were screened, with an added discovery of 13 positive cases. Therefore, the
experiences of these individuals who were faced with unexpected genetic information
that has personal medical, prognostic and family health consequences and their responses
to the information, how they dealt with it emotionally and practically, and their relatives’
willingnesstolearnabouttheirrisks,willbeusefulininformingthisdiscussion.
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